I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, announces that it entered into a definitive agreement to acquire 100% ownership of Bridge Health Biotech Co., Ltd. (Bridge Health). The transaction provides I-Mab with the rights to bispecific and multi-specific applications (including bispecific and multi-specific antibodies and antibody drug conjugates (ADCs)), based on the Claudin 18.2 (CLDN18.2) parental antibody used in the Company’s CLDN18.2 x 4-1BB bispecific antibody, givastomig.
Read the full article: I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health //
Source: https://www.globenewswire.com/news-release/2025/07/17/3117097/0/en/I-Mab-Strengthens-Givastomig-Intellectual-Property-Portfolio-through-Acquisition-of-Bridge-Health.html